Abbott MediaRoom (Product) http://abbott.mediaroom.com/ Abbott's HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant http://abbott.mediaroom.com/2018-10-19-Abbotts-HeartMate-3-Heart-Pump-Now-FDA-Approved-for-Advanced-Heart-Failure-Patients-Not-Eligible-for-a-Heart-Transplant - Advanced heart failure patients who will live with their device for the rest of their life now have access to a heart pump backed by the industry's strongest long-term data Fri, 19 Oct 2018 09:00:00 -0400 http://abbott.mediaroom.com/2018-10-19-Abbotts-HeartMate-3-Heart-Pump-Now-FDA-Approved-for-Advanced-Heart-Failure-Patients-Not-Eligible-for-a-Heart-Transplant Abbott′s FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe http://abbott.mediaroom.com/2018-10-01-Abbott-s-FreeStyle-R-Libre-2-with-Optional-Real-Time-Alarms-Secures-CE-Mark-for-Use-in-Europe - New features further enhance Abbott′s market leading sensor-based continuous glucose monitoring technology Mon, 01 Oct 2018 08:00:00 -0400 http://abbott.mediaroom.com/2018-10-01-Abbott-s-FreeStyle-R-Libre-2-with-Optional-Real-Time-Alarms-Secures-CE-Mark-for-Use-in-Europe Abbott Receives CE Mark for First Troponin Test to Help Predict the Chance of Heart Attack in Apparently Healthy Adults Potentially Months to Years in Advance http://abbott.mediaroom.com/2018-09-26-Abbott-Receives-CE-Mark-for-First-Troponin-Test-to-Help-Predict-the-Chance-of-Heart-Attack-in-Apparently-Healthy-Adults-Potentially-Months-to-Years-in-Advance - Research shows adding Abbott's High Sensitive Troponin-I diagnostic test to doctors' existing standard of care can help more accurately determine a person's chances of a heart attack or other cardiac event potentially months to years in advance Wed, 26 Sep 2018 18:01:00 -0400 http://abbott.mediaroom.com/2018-09-26-Abbott-Receives-CE-Mark-for-First-Troponin-Test-to-Help-Predict-the-Chance-of-Heart-Attack-in-Apparently-Healthy-Adults-Potentially-Months-to-Years-in-Advance One-Year Results from Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis http://abbott.mediaroom.com/2018-09-25-One-Year-Results-from-Real-World-Study-Showed-Abbotts-Portico-TM-Transcatheter-Aortic-Valve-Safely-and-Successfully-Reduced-Severe-Aortic-Stenosis - Late-breaking data from real-world experience with the first fully repositionable and retrievable valve were consistent with previous results, and support that Portico can be successfully used in various anatomies in a real-world setting Tue, 25 Sep 2018 14:45:00 -0400 http://abbott.mediaroom.com/2018-09-25-One-Year-Results-from-Real-World-Study-Showed-Abbotts-Portico-TM-Transcatheter-Aortic-Valve-Safely-and-Successfully-Reduced-Severe-Aortic-Stenosis Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation http://abbott.mediaroom.com/2018-09-23-Landmark-Study-Shows-Treatment-with-Abbotts-MitraClip-R-is-Superior-to-Medical-Therapy-for-Advanced-Heart-Failure-Patients-with-Significant-Secondary-Mitral-Regurgitation - The COAPT trial met both the primary safety and efficacy endpoints and all secondary endpoints, including reducing all-cause mortality through two years Sun, 23 Sep 2018 13:20:00 -0400 http://abbott.mediaroom.com/2018-09-23-Landmark-Study-Shows-Treatment-with-Abbotts-MitraClip-R-is-Superior-to-Medical-Therapy-for-Advanced-Heart-Failure-Patients-with-Significant-Secondary-Mitral-Regurgitation